RB Doubles R&D Spend In Search Of 'Game Changing’ OTC Innovation
Executive Summary
With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.
You may also be interested in...
Reckitt Offloads Troubled Chinese Infant Nutrition Business
Reckitt is to divest its Chinese infant formula business in a deal worth $2.2bn following a strategic review of the troubled unit.
Reckitt's OTC Sales Slide 40% In 'Exceptionally Weak' Cold & Flu Season
Reckitt reports major drop in OTC sales in Q1 as the cold and flu season was almost wiped out by social distancing measures related to COVID-19. CEO Laxman Narasimhan reveals he has seen green shoots in certain markets where restrictions have started to relax, insisting "there is no question flu will come back."
RB Shows Scholl The Door, While Welcoming In Biofreeze
Reckitt is refocusing its consumer health portfolio by offloading the troubled Scholl brand and acquiring fast-growing US topical analgesic Biofreeze.